Assessing an Oral Bruton Tyrosine Kinase Inhibitor, DZD9008 in Patients Who Have Non-Hodgkin B-cell Lymphoma (WU-KONG3)
Status:
Suspended
Trial end date:
2023-07-01
Target enrollment:
Participant gender:
Summary
This study will treat patients with non-Hodgkin B-cell lymphoma who have relapsed from,
refractory or intolerant to prior therapy. This study will help understand what type of side
effects may occur with the drug treatment. It will also measure the levels of drug in the
body and preliminarily assess its anti-cancer activity as monotherapy.